Eradivir

📍 West Lafayette, United States🗓 Founded 2020👥 9 employees💰 Last funded Jul 2023
Biotechnology Research🌐 eradivir.com
Website LinkedIn
Our overarching goal is to focus the power of a patient’s immune system to kill both viruses and virus-infected cells, thereby eliminating a viral infection without causing damage to any uninfected cells. To achieve this, we employ a novel bispecific immunotherapy that eradicates a virus by tethering a patient’s cytotoxic immune cells specifically to the pathogenic virus or virus-infected cell, i.e. facilitating the rapid and selective destruction of the virus by the patient’s immune system. With a toolkit of these small bispecific molecules, we will be able to treat and potentially cure influenza, multiple coronaviruses, hepatitis B, HIV, and even cancers without damaging a patient’s healthy cells.
2
Total investors
0
Early stage
2
Mid stage
0
Late stage
2020
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Eradivir?
Eradivir has 2 investors on record on gritt.io, 2 mid-stage.
When did Eradivir last raise funding?
The most recent investment in Eradivir recorded on gritt.io was in July 2023.
When was Eradivir founded?
Eradivir was founded in 2020.
What industry is Eradivir in?
Eradivir operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Eradivir based?
Eradivir is headquartered in West Lafayette, United States.